Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 55 opinions in the last 12 months.
Eli Lilly & Co. (LLY) has emerged as a strong player in the healthcare sector, particularly driven by its diabetes and obesity treatments which continue to propel sales and earnings forecasts. Analysts emphasize its robust growth profile, potential in the weight-loss drug market, and a strong pipeline that includes expansions into broader areas like inflammatory bowel diseases and Alzheimer's treatments. Despite its high valuation metrics, many experts maintain a positive outlook on LLY's ability to innovate and capture market share from competitors. The company's significant investments in manufacturing, marked momentum in stock performance, and excellent fundamentals underpin their hopeful projections for future growth. However, some analysts caution about its current valuation, viewing it as high relative to its peers, alongside concerns regarding future competition and the sustainability of its growth trajectory.
He owns a small holding. Likes their growth profile from their weight-loss drug; they will continue to take market share from Novo Nordisk. The big news this week was that drug shortages were over. They lowered the price too. But shares are expensive at 20x PE on 2028 numbers--expensive for a pharmaceutical. It's had a big run, so he's not adding shares, but trimming.
Eli Lilly & Co. is a American stock, trading under the symbol LLY-N on the New York Stock Exchange (LLY). It is usually referred to as NYSE:LLY or LLY-N
In the last year, 42 stock analysts published opinions about LLY-N. 24 analysts recommended to BUY the stock. 12 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Eli Lilly & Co..
Eli Lilly & Co. was recommended as a Top Pick by on . Read the latest stock experts ratings for Eli Lilly & Co..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
42 stock analysts on Stockchase covered Eli Lilly & Co. In the last year. It is a trending stock that is worth watching.
On 2025-04-28, Eli Lilly & Co. (LLY-N) stock closed at a price of $877.07.
They report Thursday. Their last report laid an egg, but expects this one to be better, so he will hold on.